about
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsOncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsCross-species models of human melanomaIntermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case seriesThe Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF KinaseCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistanceIntra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanomaAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KInterface of signal transduction inhibition and immunotherapy in melanoma.Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensionsDiscrepant alterations in main candidate genes among multiple primary melanomasDevelopment and validation of a clinical trial patient stratification assay that interrogates 27 mutation sites in MAPK pathway genes.Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cellsA meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.Using genetics and genomics strategies to personalize therapy for cancer: focus on melanomaPhosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3.Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.Ocular melanoma: an overview of the current status.Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testingNovel targeted therapies for the treatment of metastatic melanoma.Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life settingClinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceCorrelation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaRSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growthIntra-tumor heterogeneity of BRAF V600E mutation in lung adenocarcinomas.Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress.PP2B and ERK1/2 regulate hyaluronan synthesis of HT168 and WM35 human melanoma cell linesA Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy AgentsBRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade gliomaIncreased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.CRAF R391W is a melanoma driver oncogeneMolecular targeted therapies in metastatic melanoma.Paeoniflorin ameliorates acute necrotizing pancreatitis and pancreatitis‑induced acute renal injury
P2860
Q24598792-15F414EC-9CA6-4BBB-BF77-37AF326B6B45Q26774625-60F55210-FCB2-48E6-93AD-5560904F488BQ26782090-F0F58B02-AC1D-4EE5-8295-26760335B25CQ27015875-275D4B31-6F46-4CE2-9526-A0898F852518Q27654846-22E173F7-213D-438B-A052-F1A76835B0B5Q27853202-5317477B-EB27-44CA-BFF1-C5ECC3007C45Q28282963-D8728564-7512-4908-9B62-C370E6C549DAQ28740547-DD34404A-F181-4723-8FD1-5A8AC140E62CQ29614757-380F4DB8-57D6-46EF-9FD5-788255CDEA91Q30429380-0E33CE1A-DF55-462C-9331-A95E02344F06Q30486572-4E23A36A-3F5A-4B60-A103-A7B24F7448C0Q30578299-2A765170-A945-4143-B5FB-40F6FE9FA3D9Q31132555-6F7B5A5A-423E-4574-8822-E4486EEA76E0Q33699419-CB89A462-2C8A-4000-92CD-3008BD40309DQ33775637-41DF70BD-D198-4E75-A745-E89CAFF9329AQ33875566-EF7BFB9E-C716-4003-90F7-7B8ABF5459CCQ33965328-7B488A89-0946-470F-A28C-D5DB7A3EAF2EQ33971905-39FFD9AB-03F6-4861-AF8B-BA8FE300C465Q34209735-530B0CB1-A00F-4185-A4AC-B3E0932F51C9Q34622439-EB71572E-914C-48F8-8688-F9A986F337BAQ34653896-DC6BD7BD-E30B-49AE-8706-D06979C2ADB6Q34678882-751561CF-99BF-4DF4-930D-D722AC17F100Q34892977-95A90BF7-8768-4999-9D7D-C74C44B083C9Q34970350-7B178E64-3D59-40EB-9D7B-20D83B605EF7Q34986178-8B2FAE77-9E8C-4964-A2BC-E66D00E001FFQ35196177-58A8F6CB-4CE9-4600-B9AF-6387160D0898Q35273776-9BC7804B-174A-4F88-8FD9-F9725B2BCF24Q35506764-BF3EFCFD-AF70-4114-A591-0E249416E97AQ35607456-D2D5FE50-1093-4135-9849-EE93C7CC7E87Q35621653-B6F7A2A8-8DAF-42E3-BC80-C834D6C29332Q35634079-716EE775-D17E-41F9-A1AC-FE1B9AD00867Q35681430-9890F00B-4FAF-450B-825C-CAD947FCA73AQ36072016-C2360424-2293-473A-AF7A-F08D4BA9C7E2Q36571472-13311037-4BFD-4B82-A8B6-55E41FE92BF5Q36773500-A6EB17CE-F3E7-4992-977C-7F7585324712Q36811872-9D5628E1-735B-4A65-83EA-C7B21CFE4C07Q36882715-A8C5F610-5587-4177-A76A-4F2C67564725Q36980239-57C89E7F-A134-4011-9A28-7A2EC0979704Q36984179-51DD671E-3510-4BDE-A131-8042EFCE6942Q37083073-2FAA73D6-4748-437F-A8F6-98A9CC619819
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The MAPK pathway in melanoma.
@en
The MAPK pathway in melanoma.
@nl
type
label
The MAPK pathway in melanoma.
@en
The MAPK pathway in melanoma.
@nl
prefLabel
The MAPK pathway in melanoma.
@en
The MAPK pathway in melanoma.
@nl
P1476
The MAPK pathway in melanoma.
@en
P2093
Leslie A Fecher
Ravi K Amaravadi
P304
P356
10.1097/CCO.0B013E3282F5271C
P577
2008-03-01T00:00:00Z